Attacking c-Myc: Targeted and combined therapies for cancer

Current Pharmaceutical Design

Volumn 20, Issue 42, 2014, Pages 6543-6554

  Huang, Huilin ^a   Weng, Hengyou ^a   Zhou, Hui ^a   Qu, Lianghu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

C Myc; Combined therapy; MicroRNA; Natural agent; Targeted cancer therapy

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BENZODIAZEPINE DERIVATIVE; BZ 423; CETUXIMAB; CHLORPROMAZINE; COMPLEMENTARY DNA; COMPLEMENTARY RNA; DIHYDROARTEMISININ; DOUBLE STRANDED DNA; GUANINE QUADRUPLEX; IMATINIB; MICRORNA; MYC PROTEIN; NEUROLEPTIC AGENT; NICKEL COMPLEX; OLIGONUCLEOTIDE; ORIDONIN; PACLITAXEL; PROCHLOROPERAZINE; PROMAZINE; PROTEASOME; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRASTUZUMAB; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CELL GROWTH; CHROMOSOME TRANSLOCATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENOMIC INSTABILITY; GROWTH INHIBITION; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TRANSCRIPTION REGULATION; TRIPLE HELIX; UBIQUITINATION; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84911497279     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140826153203     Document Type: Article

References (161)

1. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2: 331-41.
2. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-37.
3. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 2002; 297: 63-4.
4. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199-207.
5. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297: 102-4.
6. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002; 109: 321-34.
7. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-76.
8. Felsher DW. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer 2010; 1: 597-604.
9. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3-7.
10. Capdeville R, Silberman S. Imatinib: a targeted clinical drug development. Semin Hematol 2003; 40: 15-20.
11. Baselga J, Albanell J. Targeting epidermal growth factor receptor in lung cancer. Curr Oncol Rep 2002; 4: 317-24.
12. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16: 318-30.
13. Prochownik EV, Vogt PK. Therapeutic Targeting of Myc. Genes Cancer 2010; 1: 650-9.
14. Huang HL, Weng HY, Wang LQ, et al. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther 2012; 11: 1155-65.
15. Lu JJ, Meng LH, Shankavaram UT, et al. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010; 80: 22-30.
16. Bishop JM. Retroviruses and cancer genes. Adv Cancer Res 1982; 37: 1-32.
17. Battey J, Moulding C, Taub R, et al. The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell 1983; 34: 779-87.
18. Hann SR, Sloan-Brown K, Spotts GD. Translational activation of the non-AUG-initiated c-myc 1 protein at high cell densities due to methionine deprivation. Genes Dev 1992; 6: 1229-40.
19. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem 2008; 19: 2321-31.
20. Spotts GD, Patel SV, Xiao Q, Hann SR. Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins. Mol Cell Biol 1997; 17: 1459-68.
21. Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991; 251: 1211-7.
22. Prendergast GC, Lawe D, Ziff EB. Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation. Cell 1991; 65: 395-407.
23. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN and Weintraub H. Sequence-specific DNA binding by the c-Myc protein. Science 1990; 250: 1149-51.
24. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 1992; 359: 423-6.
25. Luscher B, Larsson LG. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene 1999; 18: 2955-66.
26. Kato GJ, Barrett J, Villa-Garcia M, Dang CV. An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 1990; 10: 5914-20.
27. Stone J, de Lange T, Ramsay G, et al. Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol Cell Biol 1987; 7: 1697-709.
28. Sarid J, Halazonetis TD, Murphy W, Leder P. Evolutionarily conserved regions of the human c-myc protein can be uncoupled from transforming activity. Proc Natl Acad Sci USA 1987; 84: 170-3.
29. Freytag SO, Dang CV, Lee WM. Definition of the activities and properties of c-myc required to inhibit cell differentiation. Cell Growth Differ 1990; 1: 339-43.
30. Goruppi S, Gustincich S, Brancolini C, Lee WM, Schneider C. Dissection of c-myc domains involved in S phase induction of NIH3T3 fibroblasts. Oncogene 1994; 9: 1537-44.
31. Herold S, Wanzel M, Beuger V, et al. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 2002; 10: 509-21.
32. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002; 419: 729-34.
33. van de Wetering M, Sancho E, Verweij C, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-50.
34. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6: 635-45.
35. Moroy T, Saba I, Kosan C. The role of the transcription factor Miz-1 in lymphocyte development and lymphomagenesis-Binding Myc makes the difference. Semin Immunol 2011; 23: 379-87.
36. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003; 17: 1115-29.
37. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003; 100: 8164-9.
38. Mitchell KO, Ricci MS, Miyashita T, et al. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res 2000; 60: 6318-25.
39. Tsuneoka M, Koda Y, Soejima M, Teye K, Kimura H. A novel myc target gene, mina53, that is involved in cell proliferation. J Biol Chem 2002; 277: 35450-9.
40. Gaubatz S, Meichle A, Eilers M. An E-box element localized in the first intron mediates regulation of the prothymosin alpha gene by c-myc. Mol Cell Biol 1994; 14: 3853-62.
41. Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J 1991; 10: 133-41.
42. Miltenberger RJ, Sukow KA, Farnham PJ. An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. Mol Cell Biol 1995; 15: 2527-35.
43. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997; 94: 6658-63.
44. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 1993; 90: 7804-8.
45. Sears R, Ohtani K, Nevins JR. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol 1997; 17: 5227-35.
46. Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J 1994; 13: 4070-9.
47. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
48. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.
49. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-43.
50. Chiariello M, Marinissen MJ, Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol 2001; 3: 580-6.
51. Steelman LS, Chappell WH, Abrams SL, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3: 192-222.
52. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501-14.
53. Hermeking H. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets 2003; 3: 163-75.
54. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79: 7824-7.
55. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001; 20: 5595-610.
56. Drach J, Kaufmann H, Urbauer E, Schreiber S, Ackermann J, Huber H. The biology of multiple myeloma. J Cancer Res Clin Oncol 2000; 126: 441-7.
57. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci USA 2000; 97: 228-33.
58. Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004; 121: 384-92.
59. Miranda Peralta EI, Valles Ayoub Y, Hernandez Mendoza L, et al. [MYC protein and proteins antigenically related with MYC in acute lymphoblastic leukemia]. Rev Invest Clin 1991; 43: 139-45.
60. Kraehn GM, Utikal J, Udart M, et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer 2001; 84: 72-9.
61. Treszl A, Adany R, Rakosy Z, et al. Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation. Cytometry B Clin Cytom 2004; 60: 37-46.
62. Masramon L, Arribas R, Tortola S, Perucho M, Peinado MA. Moderate amplifications of the c-myc gene correlate with molecular and clinicopathological parameters in colorectal cancer. Br J Cancer 1998; 77: 2349-56.
63. Camps J, Nguyen QT, Padilla-Nash HM, et al. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer 2009; 48: 1002-17.
64. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992; 52: 1107-13.
65. Kreipe H, Feist H, Fischer L, et al. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 1993; 53: 1956-61.
66. Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1983; 306: 194-6.
67. Saksela K, Bergh J, Lehto VP, Nilsson K, Alitalo K. Amplification of the c-myc oncogene in a subpopulation of human small cell lung cancer. Cancer Res 1985; 45: 1823-7.
68. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 1990; 38: 340-2.
69. Sato H, Minei S, Hachiya T, Yoshida T and Takimoto Y. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients. Int J Urol 2006; 13: 761-6.
70. Abe W, Nasu K, Nakada C, Kawano Y, Moriyama M, Narahara H. miR-196b targets c-myc and Bcl-2 expression, inhibits proliferation and induces apoptosis in endometriotic stromal cells. Hum Reprod 2013; 28: 750-61.
71. Rabbitts TH, Hamlyn PH, Baer R. Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 1983; 306: 760-5.
72. Johnston JM, Carroll WL. c-myc hypermutation in Burkitt's lymphoma. Leuk Lymphoma 1992; 8: 431-9.
73. Albert T, Urlbauer B, Kohlhuber F, Hammersen B, Eick D. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines. Oncogene 1994; 9: 759-63.
74. Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 1994; 14: 5510-22.
75. Wang X, Cunningham M, Zhang X, et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 2011; 71: 925-36.
76. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000; 95: 2104-10.
77. Zhang X, Farrell AS, Daniel CJ, et al. Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci USA 2012; 109: 2790-5.
78. Bazarov AV, Adachi S, Li SF, Mateyak MK, Wei S, Sedivy JM. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res 2001; 61: 1178-86.
79. Simonsson T, Henriksson M. c-myc Suppression in Burkitt's lymphoma cells. Biochem Biophys Res Commun 2002; 290: 11-5.
80. Kim HG, Miller DM. Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter. Biochemistry 1995; 34: 8165-71.
81. McGuffie EM, Pacheco D, Carbone GM, Catapano CV. Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells. Cancer Res 2000; 60: 3790-9.
82. McGuffie EM, Catapano CV. Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene. Nucleic Acids Res 2002; 30: 2701-9.
83. Napoli S, Negri U, Arcamone F, Capobianco ML, Carbone GM, Catapano CV. Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells. Nucleic Acids Res 2006; 34: 734-44.
84. Carbone GM, McGuffie E, Napoli S, et al. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene. Nucleic Acids Res 2004; 32: 2396-410.
85. Grand CL, Han H, Munoz RM, et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 2002; 1: 565-73.
86. Agarwal T, Roy S, Chakraborty TK, Maiti S. Selective targeting of G-quadruplex using furan-based cyclic homooligopeptides: effect on c-MYC expression. Biochemistry 2010; 49: 8388-97.
87. Ou TM, Lu YJ, Zhang C, et al. Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives. J Med Chem 2007; 50: 1465-74.
88. Liao SR, Zhou CX, Wu WB, et al. 12-N-Methylated 5, 6-dihydrobenzo[c]acridine derivatives: a new class of highly selective ligands for c-myc G-quadruplex DNA. Eur J Med Chem 2012; 53: 52-63.
89. Castillo-Gonzalez D, Perez-Machado G, Guedin A, Mergny JL, Cabrera-Perez MA. FDA-approved drugs selected using virtual screening bind specifically to G-quadruplex DNA. Curr Pharm Des 2013; 19: 2164-73.
90. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-17.
91. Heikkila R, Schwab G, Wickstrom E, et al. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 1987; 328: 445-9.
92. Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol 1988; 8: 963-73.
93. Prochownik EV, Kukowska J, Rodgers C. c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells. Mol Cell Biol 1988; 8: 3683-95.
94. Harel-Bellan A, Ferris DK, Vinocour M, Holt JT, Farrar WL. Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J Immunol 1988; 140: 2431-5.
95. Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 1995; 55: 1379-84.
96. Huang Y, Snyder R, Kligshteyn M, Wickstrom E. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with anti-c-myc DNA phosphorothioate. Mol Med 1995; 1: 647-58.
97. Smith JB, Wickstrom E. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. J Natl Cancer Inst 1998; 90: 1146-54.
98. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002; 62: 3126-31.
99. Leonetti C, Biroccio A, Benassi B, et al. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther 2001; 8: 459-68.
100. Zhang YM, Rusckowski M, Liu N, Liu C, Hnatowich DJ. Cationic liposomes enhance cellular/nuclear localization of 99mTc-antisense oligonucleotides in target tumor cells. Cancer Biother Radiopharm 2001; 16: 411-9.
101. Junghans M, Kreuter J, Zimmer A. Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res 2000; 28: E45.
102. Boffa LC, Scarfi S, Mariani MR, et al. Dihydrotestosterone as a selective cellular/nuclear localization vector for anti-gene peptide nucleic acid in prostatic carcinoma cells. Cancer Res 2000; 60: 2258-62.
103. Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics. Curr Cancer Drug Targets 2001; 1: 177-96.
104. Gewirtz AM. Oligonucleotide therapeutics: clothing the emperor. Curr Opin Mol Ther 1999; 1: 297-306.
105. Clark RE. Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia 2000; 14: 347-55.
106. Chen JP, Lin C, Xu CP, et al. Molecular therapy with recombinant antisense c-myc adenovirus for human gastric carcinoma cells in vitro and in vivo. J Gastroenterol Hepatol 2001; 16: 22-8.
107. Ebinuma H, Saito H, Kosuga M, et al. Reduction of c-myc expression by an antisense approach under Cre/loxP switching induces apoptosis in human liver cancer cells. J Cell Physiol 2001; 188: 56-66.
108. Wang YH, Liu S, Zhang G, et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005; 7: R220-8.
109. Luoto KR, Meng AX, Wasylishen AR, et al. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res 2010; 70: 8748-59.
110. Shen L, Zhang C, Ambrus JL, Wang JH. Silencing of human c-myc oncogene expression by poly-DNP-RNA. Oligonucleotides 2005; 15: 23-35.
111. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007; 67: 9762-70.
112. He XY, Chen JX, Zhang Z, Li CL, Peng QL, Peng HM. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J Cancer Res Clin Oncol 2010; 136: 1023-8.
113. Lan FF, Wang H, Chen YC, et al. Hsa-let-7g inhibits proliferation of hepatocellular carcinoma cells by downregulation of c-Myc and upregulation of p16(INK4A). Int J Cancer 2011; 128: 319-31.
114. Nadiminty N, Tummala R, Lou W, et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem 2012; 287: 1527-37.
115. Wong TS, Man OY, Tsang CM, et al. MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J Cancer Res Clin Oncol 2011; 137: 415-22.
116. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106: 3207-12.
117. Chen Z, Zeng H, Guo Y, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 2010; 29: 151.
118. Lal A, Navarro F, Maher CA, et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell 2009; 35: 610-25.
119. Yamada Y, Hidaka H, Seki N, et al. Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. Cancer Sci 2013; 104: 304-12.
120. Jung HM, Patel RS, Phillips BL, et al. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell 2013; 24: 1638-48, S1-7.
121. Miao LJ, Huang SF, Sun ZT, et al. MiR-449c targets c-Myc and inhibits NSCLC cell progression. FEBS Lett 2013; 587: 1359-65.
122. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature 2009; 458: 438-44.
123. Yada M, Hatakeyama S, Kamura T, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23: 2116-25.
124. von der Lehr N, Johansson S, Wu S, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003; 11: 1189-200.
125. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell 2003; 11: 1177-88.
126. Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene 2013; 32: 1284-95.
127. Sundberg TB, Ney GM, Subramanian C, Opipari AW, Jr., Glick GD. The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-myc protein for rapid and specific degradation. Cancer Res 2006; 66: 1775-82.
128. Li Q, Kluz T, Sun H, Costa M. Mechanisms of c-myc degradation by nickel compounds and hypoxia. PLoS One 2009; 4: e8531.
129. Hatakeyama S, Watanabe M, Fujii Y, Nakayama KI. Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation. Cancer Res 2005; 65: 7874-9.
130. Cong F, Zhang J, Pao W, Zhou P, Varmus H. A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol 2003; 4: 10.
131. Berg T, Cohen SB, Desharnais J, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci USA 2002; 99: 3830-5.
132. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003; 22: 6151-9.
133. Wang H, Hammoudeh DI, Follis AV, et al. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 2007; 6: 2399-408.
134. Mo H, Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc Natl Acad Sci USA 2006; 103: 6344-9.
135. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3: 448-57.
136. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
137. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
138. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511-21.
139. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2.
140. Sasaki N, Kuroda J, Nagoshi H, et al. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp Hematol 2011; 39: 817-28 e1.
141. Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin Cancer Res 2005; 11: 1990-8.
142. Leonetti C, Biroccio A, DAngelo C, Semple SC, Scarsella M, Zupi G. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate 2007; 67: 1475-85.
143. Fei R, Shaoyang L. Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line. Gynecol Oncol 2002; 85: 40-4.
144. Hung L, Kumar V. Specific inhibition of gene expression and transactivation functions of hepatitis B virus X protein and c-myc by small interfering RNAs. FEBS Lett 2004; 560: 210-4.
145. Citro G, D'Agnano I, Leonetti C, et al. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998; 58: 283-9.
146. Leonetti C, Biroccio A, Candiloro A, et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 1999; 5: 2588-95.
147. Stewart DA, Xu X, Thomas SD, Miller DM. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression. Nucleic Acids Res 2002; 30: 2565-74.
148. Lin CP, Liu JD, Chow JM, Liu CR, Liu HE. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 2007; 18: 161-70.
149. Xie XK, Yang DS, Ye ZM, Tao HM. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines. Chemotherapy 2009; 55: 433-40.
150. Bidwell GL, 3rd, Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 2006; 71: 248-56.
151. Pastorino F, Mumbengegwi DR, Ribatti D, Ponzoni M, Allen TM. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release 2008; 126: 85-94.
152. Christensen LA, Finch RA, Booker AJ, Vasquez KM. Targeting oncogenes to improve breast cancer chemotherapy. Cancer Res 2006; 66: 4089-94.
153. Boulware SB, Christensen LA, Thames H, Coghlan L, Vasquez KM, Finch RA. Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer. Mol Carcinog 2013; DOI: 10. 1002/mc. 22026.
154. Zhang Y, Peng L, Mumper RJ, Huang L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 2013; DOI; 10. 1016/j. biomaterials. 2013. 07. 050.
155. Weng HY, Huang HL, Dong BW, Zhao PP, Zhou H, Qu LH. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Res 2014; DOI: 10. 1158/0008-5472. CAN-13-1748.
156. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1-11.
157. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004; 5: 501-12.
158. Horiuchi D, Kusdra L, Huskey NE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012; 209: 679-96.
159. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci USA 2010; 107: 13836-41.
160. Lin CJ, Nasr Z, Premsrirut PK, et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep 2012; 1: 325-33.
161. Kessler JD, Kahle KT, Sun T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012; 335: 348-53.